Association between the Polymorphism rs3217927 of CCND2 and the Risk of Childhood Acute Lymphoblastic Leukemia in a Chinese Population

Heng Zhang1*, Yan Zhou1*, Yaoyao Rui1*, Yaping Wang1, Jie Li2, Liuchen Rong1, Meilin Wang3, Na Tong3, Zhengdong Zhang3, Jing Chen4*, Yongjun Fang1*

1 Department of Hematology and Oncology, Nanjing Children’s Hospital Affiliated to Nanjing Medical University, Nanjing, China, 2 Department of Hematology and Oncology, Soochow Children’s Hospital Affiliated to Soochow University, Suzhou, China, 3 Department of Molecular and Genetic Toxicology, Cancer Center of Nanjing Medical University, Nanjing, China, 4 Department of Hematology and Oncology, Shanghai Children’s Medical Center Affiliated to Shanghai, Jiao Tong University, Shanghai, China

Abstract

CyclinD proteins, the ultimate recipients of mitogenic and oncogenic signals, play a crucial role in cell-cycle regulation. CyclinD2, one of the cyclinD family, is overexpressed in T-acute lymphoblastic leukemia (ALL) and B-phenotypic lymphocytic leukemia and involved in the pathogenesis of leukemias. Recent reports indicated that CCND2 polymorphisms are associated with human cancer risk, thusly we hypothesized that CCND2 gene polymorphisms may contribute to childhood ALL susceptibility. We selected the polymorphism rs3217927 located in the 3’UTR region of CCND2 to assess its associations with childhood ALL risk in a case-control study. A significant difference was found in the genotype distributions of rs3217927 polymorphism between cases and controls (P = 0.019) and homozygous GG genotype may be an increased risk factor for childhood ALL (adjusted OR = 1.84, 95% CI = 1.14–2.99). Furthermore, this increased risk was more pronounced with GG genotype among high-risk ALL (adjusted OR = 1.95, 95% CI = 1.04–3.67), low-risk ALL (adjusted OR = 2.09, 95% CI = 1.13–3.87), B-phenotype ALL patients (adjusted OR = 1.78, 95% CI = 1.08–2.95) and T-phenotype ALL patients (adjusted OR = 2.87, 95% CI = 1.16–7.13). Our results provide evidence that CCND2 polymorphism rs3217927 may be involved in the etiology of childhood ALL, and the GG genotype of rs3217927 may modulate the genetic susceptibility to childhood ALL in the Chinese population. Further functional studies and investigations in larger populations should be conducted to validate our findings.

Introduction

Pediatric cancer is now the second most common cause of death by disease in children in developed countries [1]. Acute lymphoblastic leukemia (ALL), the most common childhood malignancy, accounts for 26.8% of all pediatric cancers among children less than 15 years of age, with approximately 38 new cases per million children diagnosed with ALL each year in the developed world [2]. The peak incidence of childhood ALL occurs at age 2 to 5 years, suggesting that ALL may initiate in utero or during the infant period [2,3]. In recent decades, cure rate for childhood ALL have increased from 10% to nearly 85% due to optimized diagnosis, risk stratification, and chemotherapy protocols [4]. Nevertheless, childhood ALL remains a leading cause of cancer death in children. Understanding the potential etiologies of childhood ALL to reduce the incidence of pediatric ALL remains crucial.

It is widely accepted that the interaction between genes and the environment contributes to the pathogenesis of ALL in children. Potential molecular mechanisms implicated include sequential alterations in tumor-suppress genes, proto-oncogenes, and micro-RNA genes of hematopoietic stem cells or their committed progenitors [5]. Multiple recent studies indicate that genetic polymorphisms play an influential role in childhood ALL susceptibility, treatment response, and prognosis [6].

D-type cyclins, the ultimate recipients of mitogenic and oncogenic signals, have been recently recognized as potentially suitable molecular targets for chemotherapy due to their specific over-expression in malignancies [7–9]. The D-type cyclins (cyclinD1, cyclinD2, cyclinD3) are separately encoded by CCND1, CCND2 and CCND3. CCND2 is one of the direct transcriptional targets of Hedgehog signaling and PI3K-AKT signaling pathways [10,11]. Abnormal activation of these two pathways leads to disorders of cell proliferation, metabolism,
growth and survival, and has been proven implicated in hematologic malignancies [8,9,12]. Progression of the cell cycle is modulated via the sequential and well-ordered activation of several components. CyclinD2, one of the key components, plays an important role in regulating the G1/S transitions in cell cycle [13]. The abnormal expression of cyclinD2 may influence the repair of DNA damage and initiate of tumorigenesis, including leukemogenesis [14]. Multiple studies of inherited variation in cell cycle genes suggest that genotypes in this pathway may be associated with increased risk of breast cancer, prostate cancer, lung cancer, bladder cancer and oral cancer [15–21]. Recently, a genome-wide association study (GWAS) showed the CCND2 inherited genetic variations are associated with the risk of colorectal cancer in Europeans and Asians [22,23]. However, few studies have detected the effects of CCND2 gene polymorphisms on the risk of childhood ALL.

To detect the potential impact of CCND2 polymorphisms on the risk of developing childhood ALL in a Chinese population, we selected a tagging single nucleotide polymorphism (SNP) rs3217927 from the data for Chinese in the HapMap database (http://hapmap.ncbi.nlm.nih.gov/), which locates in the 3’ untranslated region (UTR) of CCND2. We then genotyped this SNP in 753 patients with childhood ALL and 1088 normal controls in this case control study.

Materials and Methods

Study subjects
The research protocol was approved by the Medical Ethics Committee of Nanjing Children’s Hospital affiliated to Nanjing Medical University. Written informed consent was obtained from the parents or legal guardians of all study subjects. From January 2007 to January 2013, 857 subjects with newly diagnosed childhood ALL and 1151 cancer-free controls were recruited from the Nanjing Children’s Hospital Affiliated Nanjing Medical University, Shanghai Children’s Medical Center Affiliated to Shanghai Jiao Tong University and Soochow University Affiliated Children’s Hospital. Parents or legal guardians of the all subjects were interviewed in person to collect demographic data and exposure information, including age, gender, parental alcohol use and tobacco-smoking and painting status of the home. Then the numbers of subjects were reduced into 753 cases and 1088 controls because of the missing of demographic data. The 753 cases included 291 females and 462 males, with a median age of 5 years. Subjects aged from 1 to 18 years and were genetically unrelated to ethnic Han Chinese. All subjects underwent bone marrow aspiration and the diagnosis of ALL was confirmed by morphology, immunohistochemistry, cytogenetics, and molecular biology. Risk stratification of the cases was determined uniformly according to the Suggestion of Diagnosis and Treatment of ALL in Childhood, published by the Society of Pediatrics, Chinese Medical Association in 2006. The control subjects had no history of malignant neoplasm or thrombotic disease and were age and gender matched to the cases.

Genotyping
Genomic DNA was extracted by standard protocols (Qiagen) from isolated peripheral blood lymphocytes. The CCND2 rs3217927 was genotyped with 384-well ABI 7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA) using TaqMan SNP Genotyping assay. The reaction contained 5 ng genomic DNA, TaqMan Master Mix, forward and reverse primers and probes for the wild type and the mutant allele in a total volume of 5 ul. The primer sequences were 5’-CTGCAGCAGCGGAACGAC-3’ and 5’-CCTGCAATTGATGTGATTGGA-3’, and the probes were 5’-FAM-TCGCTGAGCGGTA-MGB-3’ and 5’-HEX-CCCTCTGCAAGGG-MGB-3’, which were designed and manufactured by Nanjing Steed Biotechnology (Nanjing, China). The location of the CCND2 primer sequence is shown in Figure S1. The PCR thermal cycling amplification was performed under the following conditions: 95°C for 10 min followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. The genotype analysis was done blinded and 10% of control samples were randomly repeated for the typing reliability, proven complete concordant.

Expression levels of CCND2 mRNA
We extracted total RNA from bone marrow in 57 ALL patients from total 753 cases randomly. The total RNA was reverse transcribed into complementary DNA using ReverTra Ace qPCR RT kit (Toyobo, Tsuruga, Japan), and the complementary DNA was used for subsequent real-time PCR analysis (ABI 7300). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal quantitative control for each sample and each assay was done in triplicate. The primers used for amplification were 5’-TCATTGCTCTGTGTCAGCCACC-3’ and 5’-CAGCTCACTGAGGACACAG-3’. The PCR thermal cycling protocol consisted of 50°C for 2 min, then 95°C for 10 min followed by 45 cycles of 95°C for 15 s and 60°C for 1 min.

Statistical analysis
Hardy–Weinberg equilibrium of the genotype distribution for each SNP among the control group was examined by a goodness-of-fit χ2 test. Chi-square (χ2) test was used to evaluate the distribution differences of selected demographic characteristics as well as each allele and genotypes of rs3217927 between the cases and controls. Unconditional univariate and multivariate logistic regression analyses were performed to obtain crude and adjusted odds ratios (ORs) for estimating risk of childhood ALL and their 95% confidence intervals (CIs) with adjustment for diagnosis age, gender, parental alcohol use, tobacco-smoking and housing painting status. Independent-sample t-test was used for analyzing the results of CCND2 mRNA expression. Two-sided P values were selected and P<0.05 was considered statistically significant. All the statistical analyses were performed using Statistics Analysis System software (version 9.1; SAS Institute, Cary, NC).

Results

Characteristics of the study subjects
The frequency distributions of all subjects including selected demographic variables are summarized in Table 1. The median age of the recruited subjects was used as the age stratification standard. There was no significant difference in the distribution of age (P = 0.20) and sex (P = 0.89) and smoke (P = 0.08) between the cases and controls. However, compared with the control subjects, the cases had more parental drinkers and home painting exposure during the pregnancy of mother or after the birth (34.5% versus 21.0%, P<0.001; 35.9% versus 26.2%, P<0.001, respectively). Of the 753 ALL patients, 95 (12.6%) were T-ALL, 653 (87.0%) were B-ALL; the others (0.4%) were T-B cell biphenotypic acute lymphoblastic leukemia. Furthermore, 297 (39.4%) patients were in the low-risk, 163 (21.7%) patients were in the medium-risk and the remaining 293 (38.9%) were in the high-risk. All the variables above were further adjusted in the multivariate logistic regression analysis.
The stratified analysis of the associations between rs3217927 polymorphism and clinical features of ALL

The further stratification analysis was developed to evaluate the risk of CCND2 rs3217927 polymorphism and some clinical variables of ALL. As shown in Table 3, the increased risk was more pronounced with GG genotype among high-risk ALL (adjusted OR = 1.95, 95% CI = 1.04–3.67), low-risk ALL (adjusted OR = 2.09, 95% CI = 1.13–3.87), B-lineage ALL (B-ALL) patients (adjusted OR = 1.78, 95% CI = 1.08–2.95) and T-lineage ALL (T-ALL) patients (adjusted OR = 2.87, 95% CI = 1.16–7.13). In contrast, with the recessive model, the increased risk was found only in low-risk ALL (adjusted OR = 2.05, 95% CI = 1.12–3.76), B-phenotype ALL patients (adjusted OR = 1.71, 95% CI = 1.03–2.82) and T-phenotype ALL patients (adjusted OR = 2.53, 95% CI = 1.04–6.19). No significant associations were observed between the genotypes and risk of medium-risk ALL.

Association between CCND2 rs3217927 polymorphism and the expression levels of CCND2 mRNA

57 ALL patients with three genotypes of CCND2 (37 patients with AA genotype, 16 patients with AG genotype and 4 patients with GG genotype, respectively) were performed here. As shown in Figure 1 and Figure 2, no obvious difference was found here that A to G mutation changed the expression level of CCND2 mRNA. The expression levels of the AG carriers (P = 0.204) and the GG carriers (P = 0.999) has no significant difference with those of AA carriers. We than conduct a recessive model, no statistical significance has been found, either (P = 0.987).

Discussion

This ongoing study explored the association of CCND2 rs3217927 polymorphism in 753 newly diagnosed childhood ALL patients and 1088 cancer-free controls. We found that the G allele of CCND2 polymorphism rs3217927 has a significant association with childhood ALL in a Chinese population and may be a risk factor for the development of the disease. In the stratified analysis, strong evidence were found to prove a pronounced association between homozygous GG and high-risk ALL, low-risk ALL, T-phenotype and B-phenotype ALL subgroups, thus putting the homozygous GG a potential risk factor for ALL. As shown in Table 1, the epidemiologic data indicates that the cases had more parental alcohol consumption and house painting exposure during the pregnancy or after the birth than the controls, indicating a possible association between parental alcohol use and paint exposure with childhood ALL. Compared with adults, children may be at higher risk of environmental toxicants due to exposure differences, physiologic immaturity, higher cell growth and proliferation [24,25], although there were no observably significant statistical interactions between environmental exposure factors and the polymorphism, which is shown in Table S1.

The human CCND2 gene, located on chromosome 12p13.32 and spanning 31.6 kb, is a necessary member of the cyclinD gene family which promotes cell growth and proliferation [26]. Once induced by extracellular mitogenic environment, D cyclins will bind and activate the relative cyclin-dependent kinases CDK4 and CDK6 to form the Cyclin/CDK complexes. These complexes promote the cell cycle crossing the restriction-point and subsequently entering the phase of DNA synthesis [26]. In normal mammalian cells, the so-called check-point controls are the G1-to-S and G2-to-M transitions. The progress of cell cycle can stop and delay at these restriction-points to permit cell repairing of damaged DNA and prevent various types of mutations [27].

Table 1. Frequency distribution of selected variables between cases of childhood ALL and cancer-free controls.

| Variables                          | Cases (n = 753) | Controls (n = 1088) | p* |
|-----------------------------------|----------------|---------------------|----|
| Age (years)                       |                |                     |    |
| ≤5                                | 404            | 53.65               | 551 | 50.64 | 0.204 |
| >5                                | 349            | 46.35               | 537 | 49.36 |
| Gender                            |                |                     |    |
| Male                              | 462            | 61.35               | 671 | 61.67 | 0.890 |
| Female                            | 291            | 38.65               | 417 | 38.33 |
| Parental smoking status           |                |                     |    |
| Never                             | 314            | 41.70               | 498 | 45.77 | 0.084 |
| Ever                              | 439            | 58.30               | 590 | 54.23 |
| Parental drinking status          |                |                     |    |
| Never                             | 493            | 65.47               | 860 | 79.04 | <.0001 |
| Ever                              | 260            | 34.53               | 228 | 20.96 |
| House-painting status             |                |                     |    |
| Never                             | 483            | 64.14               | 803 | 73.81 | <.0001 |
| Ever                              | 270            | 35.86               | 285 | 26.19 |
| Immunophenotype                   |                |                     |    |
| B-ALL                             | 655            | 86.98               | -   | -     |       |
| T-ALL                             | 95             | 12.62               | -   | -     |       |
| Othera                           | 3              | 0.40                | -   | -     |       |
| Treatment branch                  |                |                     |    |
| Low risk                          | 297            | 39.41               | -   | -     |       |
| Medium risk                       | 163            | 21.65               | -   | -     |       |
| High risk                         | 293            | 38.94               | -   | -     |       |
| ALL, acute lymphoblastic leukemia; B-ALL, B-phenotype ALL; T-ALL, T-phenotype ALL; - or data not essential. | | | |
| aRepresents T-B cell biphenotypic acute lymphoblastic leukemia and other immunophenotypes. |

Association between CCND2 polymorphism and ALL risk

The observed genotype distributions and allele frequencies for CCND2 rs3217927 polymorphism in cases and controls and their associations with childhood ALL risk are presented in Table 2. The genotype frequencies of rs3217927 polymorphism among the controls were in agreement with Hardy–Weinberg equilibrium (p = 0.461). As shown in Table 2, the frequencies of AA, AG and GG genotypes were 61.5%, 32.9%, and 5.6%, among the cases, and 65.4%, 31.6%, and 3.0%, among the controls, respectively. There was a statistically significant difference in the genotype distributions of the CCND2 rs3217927 polymorphism between the cases and controls (P = 0.011).

Multivariate logistic regression analysis revealed that the homozygous GG genotype of rs3217927 was associated with an increased risk of childhood ALL compared with the homozygous AA genotype (adjusted OR = 1.94, 95% CI = 1.14–3.99), while the heterozygous AG was not (adjusted OR = 1.14, 95% CI = 0.93–1.39). We also observed an elevated risk in the recessive model of CCND2 rs3217927 polymorphisms (adjusted OR = 1.76, 95% CI = 1.10–2.85), but not in the dominant model (adjusted OR = 1.20, 95% CI = 0.99–1.46).
Over-expression of cyclin D shortens the duration of the G1-phase [14], thereby impeding the repair of damaged DNA, and may result in the development of cancer. The over-expression of cyclin D2 has been observed in many tumors including acute leukemia, and may contribute to unlimited cell division, prevention of programmed death and chemoresistance[28]. Compared with D2 has been observed in many tumors including acute leukemia, result in the development of cancer. The over-expression of cyclin

Over-expression of cyclinsD shortens the duration of the G1-phase and childhood ALL. Furthermore, the high risk of more parental alcohol consumption and house painting exposure, as well as genetic susceptibilities in rs3217927GG genotype in the subgroup, were investigated. We found that the homozygous GG genotype of the CCND2 rs3217927 correlated with a significantly increased risk of childhood ALL. This increased risk was most pronounced in high-risk ALL, low-risk ALL, B-phenotype and T-phenotype ALL patients, but not medium risk group, which may due to the lower number of samples in medium risk group reducing statistical power. A combination between AA genotype and AG genotype is performed as reference to conduct a recessive model, and the homozygous GG genotype still showed a significantly increased risk of childhood ALL, B-phenotype and T-phenotype ALL patients, but not medium risk group, which indicated the importance of the association between homozygous GG and the risk of childhood ALL. Furthermore, the high risk of more parental alcohol consumption and house painting exposure, as well as genetic susceptibilities in rs3217927GG genotype in the subgroup, were

### Table 2. Logistic regression analysis of association between the rs3217927 polymorphisms and the risk of childhood ALL.

| Genotypes | Cases (n = 753) | Controls (n = 1088) | Crude OR (95% CI) | Adjusted OR (95% CI) | P   |
|-----------|----------------|---------------------|-----------------|---------------------|-----|
| rs3217927 |               |                     |                 |                     |     |
| A>G       |               |                     |                 |                     |     |
| AA        | 463           | 61.5                | 712             | 65.4                | 1.00 (reference) | 1.00 (reference) | 0.019 |
| AG        | 248           | 32.9                | 344             | 31.6                | 1.11 (0.91 1.36) | 1.14 (0.93 1.39) | 0.222 |
| GG        | 42            | 5.6                 | 32              | 3.0                 | 2.02 (1.26 3.24) | 1.84 (1.14 2.99) | 0.013 |
| AG/GG     | 290           | 38.5                | 405             | 34.6                | 1.19 (0.98 1.44) | 1.20 (0.99 1.46) | 0.070 |
| AA/AG     | 711           | 94.4                | 1056           | 97.0                | 1.00 (reference) | 1.00 (reference) | 0.021 |
| GG        | 42            | 5.6                 | 32              | 3.0                 | 1.95 (1.22 3.12) | 1.76 (1.10 2.85) |       |
| G allele  |              | 0.22                | 0.19            |                     | 0.599 |

Table 3. Association of rs3217927 (CCND2) polymorphism with clinical risk and immunophenotype of childhood ALL.

| Genotype | Controls | Clinical risk | OR (95% CI) | Immunophenotype | OR (95% CI) |
|----------|----------|---------------|-------------|-----------------|-------------|
|          | n = 1088 | High n = 293  | Medium n = 163 | Low n = 297     | B-ALL n = 655 | T-ALL n = 95 |
|          | n %     | n %           | n %         | n %             | n %         | n % |
| AA       | 712     | 65.4          | 175         | 59.7            | 99          | 60.7 |
|          |         |               | 60.7        | 63.6            | 189         | 63.6 |
|          |         |               |             |                 | 1.00 (reference) | 1.00 (reference) |
| AG       | 344     | 31.6          | 102         | 34.8            | 56          | 34.4 |
|          |         |               | 34.4        | 30.3            | 90          | 30.3 |
|          |         |               |             |                 | 1.21 (0.92 1.61) | 1.23 (0.86 1.76) |
| GG       | 32      | 3.0           | 16          | 5.5             | 8           | 4.9 |
|          |         |               |             |                 | 1.95 (1.04 3.67) | 1.58 (0.70 3.58) |
|          |         |               |             |                 | 2.09 (1.13 3.87) | 1.16 (0.88 1.53) |
| AG/GG    | 405     | 34.6          | 118         | 40.3            | 64          | 39.3 |
|          |         |               | 39.3        | 38.4            | 108         | 38.4 |
|          |         |               |             |                 | 1.28 (0.96 1.67) | 1.26 (0.90 1.78) |
|          |         |               |             |                 | 2.09 (1.13 3.87) | 1.16 (0.88 1.53) |
| AA/AG    | 1056    | 97.0          | 277         | 94.5            | 155         | 95.1 |
|          |         |               | 95.1        | 93.9            | 279         | 93.9 |
|          |         |               |             |                 | 1.00 (reference) | 1.00 (reference) |
| GG       | 32      | 3.0           | 16          | 5.5             | 8           | 4.9 |
|          |         |               |             |                 | 1.78 (0.95 3.34) | 1.49 (0.66 3.35) |
|          |         |               |             |                 | 2.05 (1.12 3.76) | 35          |

---

*Two-sided chi-square test for either genotype distribution or allele frequencies between cases and controls.

*Adjusted for age, gender, parental drinking status, parental smoking status, and house painting status.

doi:10.1371/journal.pone.0095059.t002
observed in our study. The result above indicated ALL formation might be subjected to a variety of environmental expose and genetic factors. However, according to recent GWAS, the association between CCND2 polymorphisms and childhood ALL risk was not observed, as a possible result of ethnic differences [35–38]. It has been reported that the binding affinity between miRNA and its target mRNA may be changed by the SNPs located in miRNA target sites. The difference of those SNPs may lead to degradation of the mRNA and inhibition of the mRNA translation and its target mRNA may be changed by the SNPs located in 3'-UTR region) and ALL, we forecasted the allele-specific targeting miRNAs interacted with complementary sequence motifs of CCND2 rs3217927 [40]. Based on our bioinformatics analysis using miRanda and TargetScan Database (http://www.bioguo.org/miRNASNP/index.php), has-miR-922 and has-miR-4291 specifically binding the sequence surrounding the variant site came to our sights. Besides, we noticed that the Gibbs free energy was -19.30 kcal/mol for the rs3217927 A allele, and 0 kcal/mol for the G allele. These bioinformatics forecasts indicated that this SNP may change the conformation of the secondary structure of CCND2 itself and may affect the binding affinity between CCND2 mRNA and the miRNAs (has-miR-922 or has-miR-4291 both), which may finally alter the expression of cyclinD2. But no obvious difference was found here indicates A to G mutation changed the expression level of CCND2 mRNA. The reason for this result may be that we only have 57 ALL patients with three genotypes of CCND2 to conduct PCR assay [37 genotype AA, 16 genotype AG and 4 genotype GG, respectively]. There are not sufficient GG type samples to provide high certainty. A larger size of subjects is needed to repeat this part of experiment in the following research. Based on discussion above, it is proper to suspect that rs3217927 may influence miRNA biogenesis and function, and may contribute to susceptibility for childhood ALL. Of course, this is just one hypothesis of many unknown pathogenesis. Further functional evaluations in vitro and vivo with a larger size of samples are needed to confirm our conjecture.

Some limitations of this study should be addressed. Firstly, this study is hospital-based case-control designed, which may give rise to selection bias of subjects related with some particular genotypes. To minimize potential confounding bias, we adopt rigorous exclusion criteria about epidemiological design in recruitment of control subject which is frequency matched to cases by age, sex and ethnicity. The genotype frequencies of rs3217927 polymorphism among the controls in our study were consistent with the information provided by the HapMap Project. Secondly, when designing this experiment, we did notice that an independent validation cohort is necessary but our data was just over the minimum value of statistical power (709 cases and 709 controls), which was performed by Epicacl 2000 based on 1:1 ratio of cases to controls, expected OR 1.35, proportion controls exposed 40.0%, thresholds set on 0.05 and 80% of the calculated degree of certainty. In order to have the most trustworthy relevance, we devoted all our samples into relevance verification. Although we hold the opinion that the current data in this manuscript is enough to analyze the risk of ALL, it will be ideal to carry on a two-stage model. And we are still gathering data. Besides, it is essential to validate our results in a larger size of subjects, which we believe should be at least 4044 subjects in total containing 2022 cases and 2022 controls. This assessment was performed using Epicacl 2000 based on 1:1 ratio of cases to controls, expected OR 1.2, proportion controls exposed 35.0%, thresholds set on 0.05 and 80% of the calculated degree of certainty. Thirdly, the detailed epidemiologic data provided here is not adequate to evaluate gene-environment interaction. In order to provide more detailed interpretation of association between environmental toxic exposure and ALL, it would become an essential pre-work to acquire abundant epidemiologic exposure data and clinical information. Last but not least, our research about the gene susceptibility connected with childhood ALL is only limited on the statistics and epidemiology level and the further functional studies are warranted to validate our findings and reveal the underlying molecular mechanisms.

In conclusion, for the first time we found evidence that rs3217927 polymorphism in the cell cycle gene CCND2 may be relevant to susceptibility of Childhood ALL in a Chinese population. Further validation in a larger sample size with diverse ethnic populations and functional evaluations in vitro and vivo are warranted.
**Supporting Information**

**Figure S1**  The nucleotide localization of the CCND2 rs3217927 primer sequences.

**Table S1**  Interaction analyses of CCND2 rs3217927 and parental drinking and house-painting.

**References**

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30.

2. Kaatouch P (2010) Epidemiology of childhood cancer. Cancer Treat Rev 36: 277–305.

3. Terracini B (2011) Epidemiology of childhood cancer. Environ Health 10 Suppl 1: S8.

4. Armstrong SA, Look AT (2005) Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 23: 6306–6315.

5. Pui CH (2009) Acute lymphoblastic leukemia: introduction. Semin Hematol 46: 1–2.

6. Mrozek K, Harper DP, Aplan PD (2009) Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23: 991–1010, v.

7. Sicinska E, Aftantis I, Le Cam I, Swat W, Borowska C, et al. (2003) Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4: 451–461.

8. Buchakjian MR, Kornbluth S (2010) The engine driving the ship: metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 11: 715–727.

9. Siebert R, Willers CP, Opalka B (1996) Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Leuk Lymphoma 23: 505–520.

10. Katoh Y, Katoh M (2005) Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther 4: 1050–1054.

11. Katoh Y, Katoh M (2009) Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CHSL-RES/HEY, and GPCR-Gs-PKA signals. Int J Oncol 35: 187–192.

12. Han Y, Xia G, Tsang BK (2013) Regulation of cyclin D2 expression and degradation by follicle-stimulating hormone during rat granulosa cell proliferation in vitro. Biol Reprod 80: 57.

13. Chiles TC (2004) Regulation and function of cyclin D2 in B lymphocyte subsets. J Immunol 173: 2901–2907.

14. Ohtsubo M, Roberts JM (1993) Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259: 1908–1912.

15. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007) Association of common variation in 120 candidate genes with breast cancer risk. PLoS Genet 3: e42.

16. Driver KE, Song H, Lesureur F, Ahmed S, Barbosa-Morais NL, et al. (2008) Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population. Carcinogenesis 29: 353–354.

17. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, et al. (2004) A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 64: 1997–1999.

18. Hoggard HD 3rd, Menashe I, Shen M, Yeager M, Yuenger J, et al. (2008) Pathway-based evaluation of 389 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 29: 1938–1943.

19. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, et al. (2008) Genetic variants in cell cycle-control pathway confer susceptibility to bladder cancer. Cancer 112: 2467–2474.

20. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. (2006) Bladder cancer predisposition: a multigenic approach to DNA-averge and cell-cycle-controlled genes. Am J Hum Genet 78: 464–479.

21. Huang M, Spitz MR, Gu J, Lee JJ, Lin J, et al. (2006) Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. Carcinogenesis 27: 2034–2037.

22. Jia WH, Zhang B, Matsuo K, Shin A, Xiang YB, et al. (2013) Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. Nat Genet 45: 191–196.

23. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, et al. (2013) Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology 144: 799–807 e724.

24. Whyatt RM, Perera FP (1995) Application of biologic markers to studies of environmental risks in children and the developing fetus. Environ Health Perspect 103 Suppl 6: 105–110.

25. Perera FP (1997) Environment and cancer: who are susceptible? Science 278: 1008–1073.

26. Ely S, Di Liberto M, Nievicky R, Baagh LB, Cho HJ, et al. (2005) Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dyregulation in multiple myeloma. Cancer Res 65: 11345–11353.

27. Sherr CJ (2000) The Pizzizoler lecture: cancer cell cycles revisited. Cancer Res 60: 3690–3695.

28. Delmer A, Achenbaum-Cymbalista F, Tang R, Ramond S, Fauasset AM, et al. (1995) Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 85: 2870–2876.

29. Akagi T, Ono H, Shimomotoh K (1996) Expression of cell-cycle regulatory genes in HTLV-I infected T-cell lines: possible involvement of Tax1 in the altered expression of cyclin D2, p16Ink4 and p21Waf1/Cip1/Sdi1. Oncogene 12: 1645–1652.

30. Clapperie C, Caccinno W, Cayaund JM, Vecchione D, Berchelch A, et al. (2006) Cyclin D2 dyregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia 20: 92–96.

31. Karman K, Anderson A, Rijnowindorit H, Strombeck R, Lassen C, et al. (2006) Deregluation of cyclin D2 by juxtaposition with T-cell receptor alpha/ delta locus in 12q14.1p13(q14);positive childhood T-cell acute lymphoblastic leukaemia. Eur J Haematol 77: 27–34.

32. Mao X, Liang SB, Hurren R, Gronda M, Chow S, et al. (2011) Cyprezeptadine displays preclinical activity in myeloma and leukemia. Blood 112: 760–769.

33. Song H, Hogfold R, RAMUS SJ, Diicocio RA, Hogfold C, et al. (2008) Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival. Clin Cancer Res 14: 1090–1095.

34. Ma H, Chen J, Pan S, Dai J, Jin G, et al. (2011) Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer patients. Lung Cancer 73: 32–37.

35. Yang J, Cheng C, Yang W, Pir D, Cao X, et al. (2009) Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301: 393–403.

36. Trevino LB, Yang W, French D, Hamner SP, Carroll WL, et al. (2009) Germline genetic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 41: 1006–1010.

37. Orsi L, Rudant J, Bonaventure A, Goujon-Bellec S, Corda E, et al. (2012) Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESACLe study (SICE). Leukemia 26: 2561–2564.

38. Medina PP, Slack FJ (2008) microRNAs and cancer: an overview. Cell Cycle 7: 2495–2492.

39. Cai Y, Yu X, Hu S, Yu J (2009) A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 7: 147–154.

**Acknowledgments**

We thank Colleen H. McDonough, M.D. from Pediatric Hematology/Oncology Children’s Medical Center, Georgia Regents University for her valuable comments of this manuscript.

**Author Contributions**

Conceived and designed the experiments: YF JC. Performed the experiments: HZ YZ. Analyzed the data: HZ YR. Contributed reagents/materials/analysis tools: YW JL LR MW NT ZZ. Wrote the paper: HZ YF JC.